Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands
| العنوان: | Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands |
|---|---|
| المؤلفون: | Haiko J. Bloemendal, Niven Mehra, Marco B. Polee, Joan van den Bosch, Alphonsus J. M. van den Eertwegh, Carin A. Uyl-de Groot, Daan ten Bokkel Huinink, H. P. (Pieter) van den Berg, Andre M. Bergman, Inge M. van Oort, Malou C.P. Kuppen, Addy C. M. van de Luijtgaarden, Laurent M.C.L. Fossion, Mathijs P. Hendriks, Juleon L.L.M. Coenen, Winald R. Gerritsen, Hans M. Westgeest, A.C.M. van den Bergh, Ronald de Wit, N.I. Weijl |
| المساهمون: | Health Technology Assessment (HTA), Medical Oncology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical oncology, CCA - Cancer Treatment and quality of life |
| المصدر: | Clinical Genitourinary Cancer, 17, 5, pp. e946-e956 Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018Test Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier Clinical Genitourinary Cancer, 17, e946-e956 |
| بيانات النشر: | Elsevier BV, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, Oncology, medicine.medical_treatment, 030232 urology & nephrology, PLUS PREDNISONE, Androgen deprivation therapy, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Medicine, Neoplasm Metastasis, Netherlands, DOCETAXEL, Clinical Trials as Topic, education.field_of_study, CYCLES, Abiraterone acetate, Standard of Care, MEN, Middle Aged, CHEMOTHERAPY, Prognosis, OPEN-LABEL, ABIRATERONE ACETATE, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Docetaxel, Cabazitaxel, SAFETY, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, POSTDOCETAXEL, Taxoids, medicine.drug, Registry, medicine.medical_specialty, Urology, Population, INCREASED SURVIVAL, Antineoplastic Agents, 03 medical and health sciences, Trial eligibility, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, Real-world outcomes, education, Aged, Retrospective Studies, Chemotherapy, L-Lactate Dehydrogenase, business.industry, Prostate-Specific Antigen, medicine.disease, Survival Analysis, Trial population, Clinical trial, chemistry, business |
| الوصف: | In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.Background: Cabazitaxel has been shown to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel in the TROPIC trial. However, trial populations may not reflect the real-world population. We compared patient characteristics and outcomes of cabazitaxel within and outside trials (standard of care, SOC). Patients and Methods: mCRPC patients treated with cabazitaxel directly after docetaxel therapy before 2017 were retrospectively identified and followed to 2018. Patients were grouped on the basis of treatment within a trial or SOC. Outcomes included OS and prostate-specific antigen (PSA) response. Results: From 3616 patients in the CAPRI registry, we identified 356 patients treated with cabazitaxel, with 173 patients treated in the second line. Trial patients had favorable prognostic factors: fewer symptoms, less visceral disease, lower lactate dehydrogenase, higher hemoglobin, more docetaxel cycles, and longer treatment-free interval since docetaxel therapy. PSA response (>= 50% decline) was 28 versus 12%, respectively (P = .209). Median OS was 13.6 versus 9.6 months for trial and SOC subgroups, respectively (hazard ratio = 0.73, P =.067). After correction for prognostic factors, there was no difference in survival (hazard ratio = 1.00, P = .999). Longer duration of androgen deprivation therapy treatment, lower lactate dehydrogenase, and lower PSA were associated with longer OS; visceral disease had a trend for shorter OS. Conclusion: Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This underlines the importance of adequate estimation of trial eligibility and health status of mCRPC patients in daily practice to ensure optimal outcomes. (C) 2019 Elsevier Inc. All rights reserved. |
| وصف الملف: | application/pdf |
| تدمد: | 1558-7673 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c55db3d2d7c2abd92a4b76a9b4278c5eTest https://doi.org/10.1016/j.clgc.2019.05.018Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c55db3d2d7c2abd92a4b76a9b4278c5e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15587673 |
|---|